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EGF-related growth factors in the pathogenesis of murine
ARPKD.
Background. Epidermal growth factor (EGF), transforming
growth factor-a (TGF-a) and their receptor, EGFR, play key
roles in polycystic kidney disease (PKD) pathogenesis. Renal
expression of two related growth factors, amphiregulin and
heparin-binding EGF, has not been examined previously in
PKD. The aims of this study of murine autosomal-recessive
polycystic kidney disease (ARPKD) were (1) to characterize
amphiregulin and heparin-binding EGF expression in cystic ver-
sus normal kidneys and cells; and (2) to identify the functional
effects of abnormal EGF-related growth factor expression.
Methods. Amphiregulin and heparin-binding-EGF expres-
sion were examined by immunohistology and Western blot of
kidneys and conditionally-immortalized collecting tubule cells
obtained from cystic bpk mice (a murine model of ARPKD) and
normal littermates. EGF, TGF-a, amphiregulin, and heparin-
binding EGF in vitro effects on cystic and control collecting
tubule cells were assessed by cell proliferation, cyst fluid mito-
genicity, and EGFR activation.
Results. By immunohistology, amphiregulin and heparin-
binding EGF localized to apical and basolateral surfaces of
proximal tubule cysts > normal proximal tubules. In cystic col-
lecting tubules, heparin-binding EGF (but not amphiregulin)
localized to both apical and basolateral surfaces; whereas in
normal collecting tubules, amphiregulin and heparin-binding
EGF localized to the basolateral surface only. Increased am-
phiregulin and heparin-binding EGF expression by Western
blot was seen in cystic vs. normal kidneys and increased heparin-
binding EGF (but not amphiregulin) expression was present
in cystic collecting tubule cell lines vs. controls. EGF, TGF-a,
amphiregulin, and heparin-binding EGF were all mitogenic to
cystic > control collecting tubule cells. Immunoprecipitation of
EGF and TGF-a reduced cyst fluid mitogenicity by almost 80%,
whereas heparin-binding EGF and amphiregulin immunopre-
cipitations had minimal effects. Differential receptor activation
was also seen: Heparin-binding EGF markedly activated EGFR
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(>EGF = TGF-a > amphiregulin), with a greater effect seen
in cystic vs. control collecting tubule cells.
Conclusion. Multiple EGF-related growth factors are ab-
normally expressed in murine ARPKD and may have
differential roles in disease pathogenesis. In particular, newly
identified abnormalities in heparin-binding EGF expression in
cystic kidneys and cells may have important implications for
disease pathogenesis.
Epidermal growth factor (EGF) and transforming
growth factor-alpha (TGF-a), through activation of their
shared receptor, EGFR, play key roles in the patho-
genesis of polycystic kidney disease (PKD). Abnormal
expression of EGF [1–3], TGF-a [4–7], and EGFR [8–
10] have been demonstrated in both autosomal-recessive
and autosomal-dominant PKD. In murine autosomal-
recessive PKD (ARPKD), pharmacologic inhibition of
(1) EGFR tyrosine kinase activity; or (2) TGF-a process-
ing leads to a reduction in renal cystic enlargement and
ameliorates disease severity and deterioration of renal
function [7, 11].
In addition to EGF and TGF-a, at least four more
members of the EGF-related growth factor “family” have
been identified [12–14]. Amphiregulin, heparin-binding
EGF, betacellulin, and epiregulin share common “EGF-
like motifs” that are capable of binding and activat-
ing EGFR (ErbB-1) homodimers or heterodimers (with
other members of the ErbB receptor family). No studies,
to date, have examined the renal expression of amphireg-
ulin and heparin-binding EGF in PKD. Based on EGFR
ligand expression patterns in other diseases that overex-
press EGFR (such as malignancies) [15, 16], we hypothe-
sized that abnormal expression and/or function of multi-
ple EGFR ligands could have a role in PKD pathogenesis.
The overall aims of the study were (1) to characterize the
expression of amphiregulin and heparin-binding EGF in
kidneys and conditionally immortalized collecting tubule
(principal) cells derived from the bpk murine model of
ARPKD and normal littermates; and (2) to identify the
functional effects of abnormal EGF-related growth fac-
tor expression in murine ARPKD.
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METHODS
Animal model and cell lines
The bpk model of ARPKD arose as a spontaneous mu-
tation in a colony of Balb/C mice [17]. Bicc1 (Bicaudal
C), which localizes to mouse chromosome 10 (a region
that is not syntenic with human ARPKD), was recently
identified as the disease-causing gene [18]. However, the
mechanisms by which mutations in this gene result in cys-
tic kidney disease remain unknown. Mice homozygous
for the bpk mutation develop severe renal cystic disease
evident histologically at birth and typically die by 28 days
of age. The disease phenotype and course has been char-
acterized previously [19, 20]. In the current studies, all
animal experiments were conducted in accordance with
policies of the Institutional Animal Care and Use Com-
mittee (IACUC) of Case Western Reserve Univer-
sity. Reagents were obtained from Sigma Chemical Co.
(St. Louis, MO, USA), unless otherwise indicated.
Conditionally-immortalized principal cell collecting
tubule cell lines derived from cystic bpk mice and con-
trol littermates were maintained in defined media in per-
missive conditions, as previously described [21]. Cystic
and control collecting tubule cells (passage 10–20) were
plated on tissue-culture treated 100 mm plates or 75 cm2
flasks and grown in nonpermissive conditions (37◦C with-
out gamma-interferon) for at least 4 days prior to the start
of the experiments outlined below.
Immunohistology
Kidneys were obtained from cystic bpk mice and non-
cystic littermates at postnatal day 21. Immunohistol-
ogy was performed on 4 lmol/L sections obtained from
paraformaldehyde-fixed specimens embedded in plastic
as described (with modifications) [7, 11]. Primary anti-
bodies were rabbit polyclonal anti-human amphiregulin
(Ab-1) (Neo Markers, Fermount, CA, USA) and rabbit
antirat heparin-binding EGF (a gift from Dr. Raymond
Harris, Vanderbilt University). For this study, an amplifi-
cation step was added, using a biotinylated antirabbit sec-
ondary antibody (Vector Laboratories, Burlingame, CA,
USA) followed by application of peroxidase-conjugated
strepaviden (ExtraAviden) (Sigma, St. Louis, MO,
USA). Tubular localization of antibody staining was as-
sessed by staining serial sections with biotinylated lectins
[Lotus tetragonolobus (LTA) and Dolichos biflorus agglu-
tinin (DBA)] specific for proximal and collecting tubules
respectively, as described [7, 17, 22].
Western analysis and immunoprecipitation
Protein was isolated from day 21 cystic and con-
trol kidneys and confluent collecting tubule cell mono-
layers by homogenization in radioimmunoprecipitation
(RIPA) buffer [1 × phosphate-buffered saline (PBS),
0.5% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate (SDS), and 1% NP-40) with protease inhibitors
(0.1 mg/mL aprotinin, 5 lg/mL leupeptin, 50 lg/mL
pepstatin, 1 mmol/L ethylenediaminetetraacetic acid
(EDTA), 1 mmol/L phenylmethylsulfonyl fluoride
(PMSF), and 1:100 vol/vol phosphatase inhibitor cock-
tail] [7]. Prior to lysis, cell monolayers were washed with
PBS containing 2 mol/L NaCl to remove any heparin-
binding proteins bound to cell surface proteins. Protein
content of all samples was determined using the BCA
protein assay kit (Pierce, Rockford, IL, USA).
Cell lysates and whole kidney lysates used for am-
phiregulin and heparin-binding EGF Western analysis
were subjected to heparin column purification using Hi-
trap heparin-binding columns (Amersham Pharmacia
Biotech, Inc., Piscataway, NJ, USA), according to the
manufacturer’s specifications. Briefly, 1000 lg of each
sample was diluted in binding buffer (10 mmol/L sodium
phosphate, pH 7), run over a heparin column preequi-
librated with the same buffer, washed, and eluted with
elution buffer (10 mmol/L sodium phosphate 1.2 mol/L
NaCl, pH 7). Purified lysates were then concentrated us-
ing Centriplus 3 concentrators (Millipore, Billarica, MA,
USA) then dialyzed/desalted using Microcon 3 micro-
concentrators (Millipore). Lysates were then brought to
equal volumes with 1 × PBS and diluted in 5 × Laemlli
SDS reducing buffer (0.25 mol/L Tris-HCl, 10% SDS,
50% glycerol, 0.05% bromophenol blue, and 25% 2-ME).
For amphiregulin and heparin-binding EGF Western
analysis, equal volumes of heparin column purified pro-
tein (whole cell or whole kidney lysate), diluted in SDS
reducing buffer, were resolved by SDS-polyacrylamide
gel electrophoresis (PAGE). Samples were transferred
to nitrocellulose membranes (Bio-Rad, Hercules, CA,
USA) and hybridized with blocking buffer (5% dry milk,
0.05% Tween 20) followed by overnight incubation with
rabbit polyclonal antihuman amphiregulin (Ab-2) (Neo
Markers) at 1:125 or rabbit polyclonal antirat heparin-
binding EGF at 1:1000. Membranes were washed, hy-
bridized with the appropriate peroxidase conjugated sec-
ondary antibodies, developed with ECLTM (Amersham
Pharmacia Biotech, Inc.) and exposed to autoradiogra-
phy film.
Cyst fluid was examined for the presence of EGF, TGF-
a, amphiregulin, and heparin-binding EGF protein by
immunoprecipitation. Cyst fluid was obtained by aspira-
tion of kidneys from day 21 cystic bpk mice. Protease
inhibitors were added to obtain the same final concen-
trations as those used for tissue and cell lysates, noted
above. Antibodies used were goat anti-mouse EGF, goat
antihuman TGF-a and goat antimouse heparin-binding
EGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and AB-2. Five hundred micrograms of total cyst fluid
protein with protease inhibitors was immunoprecipitated
with 2 lg of primary antibody overnight at 4◦C followed
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by the addition of Protein A/G PLUS-agarose (Santa
Cruz Biotechnology) for 1 hour. Pellets were collected
by centrifugation, washed several times with RIPA and
resuspended in 2 × SDS reducing buffer and subjected
to Western analysis as outlined above.
Proliferation assays and assessment of cyst
fluid mitogenicity
Cystic and control collecting tubule cells grown under
non-permissive conditions were plated on 24-well plates
and grown to subconfluence (60% to 80% confluence), to
avoid the potential for cell-cell contact inhibition of pro-
liferation at higher densities. Equimolar concentration of
each growth factor (EGF, TGF-a =100 ng/mL; amphireg-
ulin and heparin-binding EGF = 150 ng/mL) was added
to the media and the cells incubated for 24 hours. Bro-
modeoxyuridine (BrdU) was added for the last 3 hours
of the incubation. Cells were fixed with paraformalde-
hyde/methanol and treated with 4 N HCl. Proliferation
was assessed by BrdU uptake as determined by immuno-
cytochemistry using biotinylated monoclonal-anti-BrdU
antibody (Zymed, S. San Francisco, CA, USA). Prolifer-
ation was reported as percentage of cells staining positive
for BrdU. At least 500 cells were counted in each sam-
ple, which were run in duplicate and each experiment
performed at least twice. Means and standard deviations
were calculated and differences between control and cys-
tic cell proliferation rates were analyzed by two-tailed
Student t test.
In additional studies, cyst fluid was sequentially im-
munoprecipitated with antibodies directed against TGF-
a, EGF, amphiregulin, and heparin-binding EGF. Cyst
fluid was incubated with antibody for 2 hours, followed
by incubation with protein A/G agarose for 1 hour to
overnight. For controls, normal goat or rabbit IgG corre-
sponding to the host species for the antibody was added to
a separate aliquot of cyst fluid and experiments run in par-
allel. Cystic cells grown in nonpermissive conditions were
treated with 10% vol/vol cyst fluid from each of the im-
munoprecipitation conditions and cell proliferation was
assessed by BrdU uptake, as above.
Detection of activated EGFR
Cystic and control collecting tubule cells grown under
nonpermissive conditions [with the addition of 5% fe-
tal bovine serum (FBS)] were plated on 100 mm plates
and grown to subconfluence. Cells were washed with PBS
and incubated at 4◦C × 4 hours with collecting tubule
media (without added FBS) or with equimolar concen-
trations of recombinant EGF (mouse, 100 ng/mL), TGF-
a (human, 100 ng/mL), amphiregulin (human, 150 ng/
mL), or heparin-binding EGF (human, 150 ng/mL) added
to the media. Total cellular protein was isolated and
immunoprecipitation was performed on 500 lg of cell
lysate as outlined above. The antibody used was rab-
bit polyclonal antihuman EGFR (Research Diagnostics,
Flanders, NJ, USA), which recognizes both activated
and nonactivated receptor. Receptor activation was as-
sessed by Western analysis using antiphosphotyrosine an-
tibody RC20:horseradish peroxidase (HRP) conjugated
(BD Transduction Laboratories, San Diego, CA, USA).
Blots were also probed with anti-EGFR to confirm equal
loading of samples.
RESULTS
Amphiregulin and heparin-binding EGF are abnormally
expressed in cystic kidneys
In order to identify qualitative or quantitative ab-
normalities in amphiregulin or heparin-binding EGF
expression in cystic kidneys compared to controls, am-
phiregulin, and heparin-binding EGF protein expression
and localization was examined by immunohistochemistry
in cystic and control kidneys (postnatal day 21, advanced
cystic kidney disease). As shown in Figure 1A and C, cys-
tic kidneys demonstrate staining for both amphiregulin
and heparin-binding EGF on the apical and basolateral
surfaces of proximal tubule cysts. In this mouse model,
proximal tubule cysts are seen early in the disease course,
mirroring the transient proximal tubule cysts seen in hu-
man ARPKD fetuses [23]. As with the human disease, in
bpk kidneys, proximal tubule cysts are replaced by col-
lecting tubule cysts as the disease progresses, although
some proximal tubule cysts persist late into the disease.
Amphiregulin and heparin-binding EGF staining of prox-
imal tubules is present in normal control kidneys as well
(Fig. 1B and D), although of less intensity. In collecting
tubule cysts (Fig. 2A), amphiregulin staining localizes to
the cytoplasm and the basolateral surface, but is not evi-
dent on the apical surface. Significant differences are not
seen in either the intensity or localization of amphiregulin
staining of collecting tubule cysts compared to control
collecting tubules (Fig. 2B). In contrast, heparin-binding
EGF staining is increased in collecting tubule cysts com-
pared to control collecting tubules (Fig. 2C vs. D). In ad-
dition, apical, as well as basolateral heparin-binding EGF
staining is seen in collecting tubule cysts. Heparin-binding
EGF staining in normal collecting tubules is confined to
the basolateral surfaces (Fig. 2D).
To further characterize expression of these growth
factors in murine ARPKD, amphiregulin and heparin-
binding EGF protein expression was examined by
Western analysis of whole kidney lysates obtained from
day 21 cystic and control kidneys and whole cell lysates
from conditionally immortalized cystic and control CT
cell lines (Figs. 3 and 4). As shown in Figure 3, increased
expression of a 45 kD immunoreactive amphiregulin
species is seen in cystic kidneys compared to controls.
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Fig. 1. Amphiregulin (AR) and heparin-
binding epidermal growth factor (HB-EGF)
expression and localization in proximal
tubules of day 21 cystic bpk and control kid-
neys. Immunohistology with polyclonal am-
phiregulin antibody AB-1 (brown staining)
in day 21 cystic (A) and control (B) kid-
neys demonstrates increased apical staining
in proximal tubule (PT) cysts compared to
normal proximal tubules (arrows). Basolat-
eral staining is present as well. Immunohis-
tology with polyclonal heparin-binding EGF
antibody (brown staining) in day 21 cystic
(C) and control (D) kidneys also demon-
strates increased apical staining in proximal
tubule cysts compared to normal proximal
tubules (arrows). More prominent basolateral
heparin-binding EGF staining is also noted
in proximal tubule cysts compared to normal
controls. Proximal tubules were localized by
serial lectin staining and identified by positive
staining for Lotus tetragonolobus and nega-
tive staining for Dolichos biflorus agglutinin
(LTA+/DBA−).
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Fig. 2. Amphiregulin (AR) and heparin-
binding epidermal growth factor (HB-EGF)
expression and localization in collecting
tubules of day 21 cystic bpk and control kid-
neys. Immunohistology with polyclonal am-
phiregulin antibody AB-1 (brown staining)
in day 21 cystic (A) and control (B) kid-
neys demonstrates basolateral amphiregulin
staining of equal intensity in collecting tubule
(CT) cysts and normal collecting tubuless
(arrows). Apical staining is not present. In
contrast, immunohistology with polyclonal
heparin-binding EGF antibody (brown stain-
ing) in day 21 cystic (C) and control (D) kid-
neys demonstrates prominent apical staining
in cystic collecting tubules but no apical stain-
ing in control collecting tubules. Basolateral
staining, present in both cystic and control
collecting tubules, is also more prominent in
the collecting tubule cysts. Collecting tubules
were localized by serial lectin staining and
identified by positive staining for Dolichos bi-
florus agglutinin and negative staining for Lo-
tus tetragonolobus (DBA+/LTA−).
There are no significant differences in amphiregulin ex-
pression in the cell lysates.
Figure 4 demonstrates that heparin-binding EGF ex-
pression is also significantly increased in cystic compared
to control kidneys. Immunoreactive species of 28 and
47 kD are seen in cystic kidneys but are not detectable in
control kidneys. With prolonged exposure to autoradio-
graphy film, a faint 47 kD band in the controls becomes
visible, but the 28 kD band is not seen (data not shown).
In the cell lysates, a 22 kD heparin-binding EGF pro-
tein species is more prominent in cystic vs. control cell
lysates. Less prominent higher-molecular-weight species
of 40 and 47 kD are also seen in the cell lysates but do not
differ significantly in intensity between cystic and control
collecting tubule cells.
Expression of each EGF-related growth factor was also
examined by immunoprecipitation of cyst fluid with an-
tibodies directed against each growth factor. As shown
in Figure 5, an immunoreactive EGF species of 6 kD
is present. Smearing of higher-molecular-weight bands
precludes identification of additional species. Recombi-
nant mouse EGF (6 kD) migrates at the expected size.
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Fig. 3. Amphiregulin (AR) protein expression in cystic and control
kidneys and collecting tubule (CT) cells. Western analysis for amphireg-
ulin, as outlined in the text, was performed on protein lysates from
whole kidneys and conditionally immortalized collecting tubule cells
from cystic bpk mice (cyst) and noncystic littermates (control). Recom-
binant human amphiregulin (molecular weight 9 kD) was loaded as a
positive control. Kidney and cell lysates were subjected to heparin col-
umn purification as outlined in the text, prior to loading. Amphiregulin
expression is increased in cystic kidneys compared to controls (45 kD
band). No differences in amphiregulin expression in cystic vs. control
collecting tubule cells are noted. Recombinant human amphiregulin
migrates at a slightly higher molecular weight of 13 kD, compared to
the expected weight of 9 kD.
A dominant TGF-a reactive species also migrates as a
broad band at approximately the same molecular weight
as recombinant human TGF-a (6 kD). The amphireg-
ulin immunoprecipitation shows a band at approximately
9 kD. Recombinant human amphiregulin (9 kD) migrates
at a slightly higher molecular weight of approximately
13 kD. Heparin-binding EGF immunoprecipitation
shows a band at approximately 9 kD as well. The recom-
binant human heparin-binding EGF migrates as a very
broad band between 9 and 25 kD. Recombinant heparin-
binding EGF, unlike the other three purified growth fac-
tor controls is derived from an insect cell line, and thus
may be susceptible to glycosylation. Nonspecific (NS)
bands of variable intensity present at approximately 30
and 55 kD, are consistent with immunoglobulin light and
heavy chains.
Cystic collecting tubule cells are hyperproliferative in
response to stimulation with EGF-related growth factors
In addition to examining endogenous expression of
amphiregulin and heparin-binding EGF in cystic and
normal tissues, collecting tubule cells and cyst fluid, we
also examined the physiologic effects of the EGF-related
growth factors (EGF, TGF-a, amphiregulin, and heparin-
binding EGF) on cystic and normal epithelium in vitro.
Figure 6 shows the proliferative response of cystic and
control collecting tubules to stimulation with equimolar
concentration of each growth factor. Baseline prolifera-
tion rates of unstimulated cells were found to be signifi-
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Fig. 4. Heparin-binding epidermal growth factor (HB-EGF) protein
expression in cystic and control kidneys and collecting tubule (CT) cells.
Western analysis for heparin-binding EGF, as outlined in the text, was
performed on protein lysates from whole kidneys and conditionally-
immortalized collecting tubule cells from cystic bpk mice (cyst) and
noncystic littermates (control). Recombinant human heparin-binding
EGF (molecular weight 9 kD) was loaded as a positive control. Kidney
and cell lysates were subjected to heparin column purification as out-
lined in the text, prior to loading. Heparin-binding EGF expression is
increased in cystic kidney lysates. Two immunoreactive heparin-binding
EGF species are evident in the cystic kidney at 28 kD and 47kD, but
neither band is detectable in the normal kidney. Heparin-binding EGF
expression is also increased (22 kD band) in cystic vs. control collecting
tubule cells. Two bands at 40 and 47 kD are present at equal intensity
in cystic and control collecting tubule cells. These may represent mod-
ified proteins, as discussed above. A broad band of variable intensity
spanning 60 to 70 kD is present in all lanes, consistent with a nonspecific
finding. The recombinant human heparin-binding EGF (9 kD) migrates
as a band spanning 10 to 12 kD.
cantly higher in cystic collecting tubule cells compared to
controls (33% BrdU-positive vs. 25%, P =0.026). All four
growth factors significantly increased proliferation rates
in cystic and control collecting tubule cells. However, the
response of cystic cells was consistently greater than that
of control cells for each growth factor examined (EGF
50% vs. 35%, P = 0.01; TGF 50% vs. 33%, P = 0.004;
amphiregulin 48% vs. 35%, P = 0.001; heparin-binding
EGF 48% vs. 37%, P = 0.017).
Immunoprecipitation of EGF-related growth factors
from cyst fluid reduces cyst fluid mitogenicity
As shown in Figure 7, treatment of cystic collecting
tubule cells with 10% cyst fluid for 24 hours increased pro-
liferation by 112% above the baseline proliferation rate.
To determine the role of each of the EGF-related growth
factors studied in mediating this mitogenic response, cyst
fluid was then subjected to sequential immunoprecipi-
tation. Immunoprecipitation with TGF-a decreased the
proliferative response by half (112% to 53%, P = 0.01).
Although immunoprecipitation with the control IgG also
reduced the baseline proliferation rate (112% to 82%,
P = 0.02), the effect of TGF-a immunoprecipitation
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Fig. 5. Immunoprecipitation of epidermal
growth factor (EGF), transforming growth
factor-a (TGF-a), amphiregulin (AR) and
heparin-binding (HB)-EGF from cyst fluid
obtained from bpk kidneys. Cyst fluid was ob-
tained from day 21 cystic bpk mice and im-
munoprecipitated with polyclonal antibodies
directed against TGF-a, EGF, amphiregulin,
or heparin-binding EGF, then subjected to
Western analysis, as described in the text. Re-
combinant growth factor was loaded as a posi-
tive control for their respective immunoblots.
Dominant immunoreactive species of approx-
imately 6 kD are present in the EGF and
TGF-a IP immunoblots (arrows). AR and
HB-EGF IP immunoblots show immunoreac-
tive species of approximately 9kD (arrows).
Nonspecific (NS) bands of variable inten-
sity present at approximately 30 and 55 kD
are consistent with immunoglobulin light and
heavy chains.
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Fig. 6. Cystic and control collecting tubule
(CT) cell proliferation in response to epi-
dermal growth factor (EGF)-related growth
factor stimulation. Cystic and control col-
lecting tubule cells were grown in non-
permissive conditions in defined media on
24-well tissue culture plates, then stimulated
with each growth factor at equimolar con-
centrations [EGF and transforming growth
factor-a (TGF-a) = 100 ng/mL, amphiregulin
(AR) and heparin-binding (HB)-EGF = 150
ng/mL] for 24 hours. Cell proliferation was de-
termined by bromodeoxyuridine (BrdU) up-
take. BrdU was added in the last 3 hours of
incubation and cells were fixed and stained
with biotinylated anti-BrdU as described in
the text. Cell proliferation is expressed as the
percentage of total cells that stain positive for
BrdU. Five hundred cells were counted for
each well and experiments were performed
in duplicate and repeated at least twice. The
figure shows the result of a representative ex-
periment. As noted in the text, baseline pro-
liferation rates were significantly higher in
cystic compared to control cells and the pro-
liferative response was consistently greater in
cystic cells versus controls (P < 0.05 cystic vs.
control) for each growth factor studied.
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Fig. 7. Sequential immunoprecipitation of epidermal growth factor (EGF)-related growth factors from cyst fluid and impact on cyst fluid mi-
togenicity. Cyst fluid obtained from day 21 cystic bpk kidneys was subjected to sequential immunoprecipitation with antibodies directed against
transforming growth factor-a (TGF-a), EGF, amphiregulin (AR) and heparin-binding (HB)-EGF as described in the text. For controls, cyst fluid was
sequentially immunoprecipitated with normal IgG corresponding to the host species of the antibody (TGF, EGF, heparin-binding EGF = goat IgG;
amphiregulin = rabbit IgG). Cystic collecting tubule cells grown in nonpermissive conditions were exposed for 24 hours to media alone, media with
10% cyst fluid (“no treatment”) or media with 10% cyst fluid from each of the sequential immunoprecipitations. Results are expressed as the percent
increase above baseline proliferation rate of the cells treated with media alone. Proliferation assays were performed in triplicate, and experiments
repeated twice. Means and standard deviations were calculated for each experimental condition and differences between treatment and control
immunoprecipitations, as well as differences between sequential immunoprecipitations (for each treatment and control immunoprecipitation) were
determined by Student t test. These are the results of a representative experiment. Untreated cyst fluid increased baseline proliferation by 112%.
Immunoprecipitation with anti-TGF-a decreased the proliferative rate by half (from 112% to 53%, P = 0.01). Although immunoprecipitation
with the control IgG also reduced the baseline proliferation rate (112% to 82%, P = 0.02), the effect of TGF-a was significantly greater than
that of control IgG (P = 0.02 cystic vs. control). Further immunoprecipitations with anti-EGF decreased the proliferative rate to 25% (P = 0.03),
whereas the control IgG was associated with only a modest reduction in proliferation rate that was not significant (85% to 71%, P = 0.2). No
further decrease in proliferative effect is seen with anti-amphiregulin immunoprecipitation. A small reduction in the proliferative rate was seen
with anti-heparin-binding EGF immunoprecipitation (decrease to 10%), but this did not reach statistical significance. No reductions in proliferative
rates were seen with the latter two control IgG immunoprecipations.
was significantly greater than that of control IgG (P =
0.02 cystic vs. control). Further immunoprecipitation with
EGF decreased the proliferative rate to 25% (P = 0.03),
whereas the control IgG was associated with only a mod-
est reduction in proliferation rate that was not significant
(85% to 71%, P = 0.2). No further decrease in prolifer-
ative effect is seen with amphiregulin immunoprecipita-
tion. A small reduction in the proliferative rate (decrease
to 10%) was seen with heparin-binding EGF immunopre-
cipitation, but this did not reach statistical significance.
No reductions in proliferative rates were seen with the
last two control IgG immunprecipitations.
EGF-like growth factors differentially activate EGFR
Finally, we examined the impact of each growth fac-
tor on EGFR activation in cystic and control collect-
ing tubule cells in vitro (Fig. 8). In untreated cystic and
control collecting tubule cells, receptor activation (as as-
sessed by EGFR phosphorylation) was not detectable.
EGF and TGF-a both activated receptor to approx-
imately the same extent. In contrast, heparin-binding
EGF treatment increased activation to a greater degree
whereas amphiregulin treatment had only minimal ef-
fects. This differential effect on EGFR phosphorylation
was greater in the cystic collecting tubule cells compared
to the controls for each of the growth factors studied.
Heparin-binding EGF treatment, in particular, markedly
increased receptor activation in cystic collecting tubule
cells.
DISCUSSION
These studies provide new evidence for abnor-
mal expression of two EGF-related growth factors,
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IP: EGFR
WB: anti-pTyr
IP: EGFR
WB: EGFR
Fig. 8. Activation of epidermal growth factor receptor (EGFR) in cystic and control collecting tubule (CT) cells in response to EGF-related growth
factor stimulation. Cystic and control collecting tubule cells were grown in non-permissive conditions in defined media [with 5% fetal bovine serum
(FBS) added] on 100 cm tissue culture plates to subconfluence. Cells were deprived of serum for 18 hours, then incubated at 4◦C for 4 hours in media
alone (without added FBS) or with equimolar concentrations of growth factor added to the media. Total cellular protein was isolated, quantified
and EGFR activation assessed by Western analysis for phosphotyrosine activity, as described in the text (upper panels). Blots were also probed
with rabbit anti-EGFR to confirm equal loading of samples (lower panels). As shown in the upper panels, all four growth factors increase EGFR
phosphorylation, although to different degrees. EGF and transforming growth factor-a (TGF-a) have similar effects on receptor activation, whereas
the effect of heparin-binding EGF is more pronounced and that of amphiregulin is minimal. In addition, growth factor-induced phosphorylation is
consistently greater for cystic vs. control cells for all four of the EGF-related growth factors studied, particularly heparin-binding EGF. The lower
panels confirm that approximately equal amounts of total EGFR were immunoprecipitated with each treatment condition.
amphiregulin and heparin-binding EGF, in murine
ARPKD. Similar to our previous findings for TGF-a
[7], increased expression of amphiregulin and heparin-
binding EGF were noted in proximal tubule cysts of
cystic ARPKD kidneys. These findings suggest the pos-
sibility that increased shedding of growth factors “up-
stream” into the urine could exert proliferative effects
distally on abnormal collecting tubule epithelia that ex-
press apical EGFR. Although some expression of both
amphiregulin and heparin-binding EGF was also seen
on the apical surfaces of normal proximal tubules, this is
less likely to have as significant a physiologic effect, since
normal postnatal collecting tubules do not express apical
EGFR.
The finding of apically expressed heparin-binding EGF
in collecting tubule cysts in murine ARPKD has sev-
eral important implications for disease pathogenesis.
Heparin-binding EGF, like other members of the EGF-
related family, is produced as a propeptide that is in-
serted into the plasma membrane. It is then cleaved
[by a protein kinase C (PKC)-dependent mechanism] to
release a secreted form [24]. The secreted form has been
shown to have a role in cell proliferation, whereas the
membrane bound forms may play a role in cell-cell and
cell-matrix interactions [25]. The presence of heparin-
binding EGF on the apical surface of cystic collecting
tubules raises the possibility that both membrane-bound
and secreted forms could activate apical EGFR present
on cystic collecting tubule epithelium [9] by autocrine
and/or paracrine mechanisms. Since membrane-bound
heparin-binding EGF promotes cell survival in cultured
renal epithelial cells and may have a role in cell-cell
and cell-matrix interactions [26], it is also possible that
abnormally expressed heparin-binding EGF could alter
these contacts and facilitate tubular expansion during
cystogenesis.
Western analysis of amphiregulin and heparin-binding
EGF protein expression in cystic and control whole kid-
ney lysates demonstrates increased expression of both
growth factors. amphiregulin protein expression in the
normal kidney has not been well-characterized, although
a role in fetal kidney branching morphogenesis has been
suggested [27]. Furthermore, the WT1 gene, which has
an important role in kidney development, has also been
shown to be a potent transcriptional activator of am-
phiregulin [27]. Multiple cellular and soluble amphireg-
ulin forms have been detected in epithelial cells ranging
from 9 to 50 kD [28, 29]. The dominant band of approx-
imately 45 kD noted in the current studies is consistent
with a published report on human amphiregulin [28]. The
faint 47 kD band seen in the collecting tubule cells only
may represent an alternatively processed membrane-
bound form, as has been described previously [28]. Since
overall kidney tissue levels of amphiregulin are increased
in the cystic vs. control kidneys but similar differences are
not present in the collecting tubule cell lysates, this sug-
gests that the abnormal expression of amphiregulin in
cystic kidneys may reside in other cell types. One candi-
date is proximal tubule cells, in which amphiregulin ex-
pression by immunohistology was increased in cystic vs.
2026 Dell et al: EGF-related growth factors in murine ARPKD
control kidneys, whereas collecting tubule cell expression
was similar cystic vs. control kidneys.
In contrast to amphiregulin, heparin-binding EGF ex-
pression in the kidney has been well characterized, par-
ticularly in the rat [30]. Heparin-binding EGF has a
role in collecting duct development and branching mor-
phogenesis [31] as well as response to injury [32]. In
the current study, heparin-binding EGF expression is
increased in cystic kidneys and collecting tubule cells
compared to controls. In whole kidney lysates, two promi-
nent immunoreactive heparin-binding EGF species at
28 kD and 47 kD are evident in the cystic kidney, but
neither band is detectable in the normal kidney. The
28 kD species is consistent with published reports of
membrane-bound species ranging in size from 25 to 30 kD
[32, 33]. The higher-molecular-weight band of 47 kD
may represent glycosylation (or other protein modifica-
tion) of membrane-bound forms. At least one study of
heparin-binding EGF expression in mice has reported
the presence of higher-molecular-weight forms [33], and
a similar faint band was present in a study of heparin-
binding EGF expression in the ischemic kidney [32].
In collecting tubule cells, heparin-binding EGF ex-
pression in cystic collecting tubule cells is also increased
(22 kD band) compared to control collecting tubule cells.
This band is smaller than the expected size for membrane-
bound forms as reported in the literature. Although band
sizes in this range have been reported for secreted pro-
teins, this clearly cannot be the explanation for the band
seen, since cell lysates would not contain secreted forms.
Alternatively, the 22 kD band may represent an alterna-
tively processed or partially cleaved membrane-bound
form. Both 40 kD and 47 kD bands of equal intensity
are present in cystic and control collecting tubule cells,
the latter in the same position as a band present in the
tissue lysates. Of note, however, the 22 kD band promi-
nent in the cystic and, to a lesser extent, control collect-
ing tubule cell lysates is not visible in the whole kidney
lysates. The most likely explanation is that the cell lysates,
which contain only elements of collecting tubule cells,
represent an “enriched source” for this protein species.
In contrast, tissue lysates contain proteins from multi-
ple different kidney cell types. Therefore, we hypothesize
that this immunoreactive heparin-binding EGF species
may be specific to cystic and, to a lesser extent con-
trol collecting tubules. This finding is further supported
by the heparin-binding EGF immunohistology results, in
which we demonstrated abnormal expression and local-
ization of heparin-binding EGF in cystic (vs. control) col-
lecting tubules, but not in proximal cysts. Increases in
heparin-binding EGF expression have been reported
in rat models of both ischemic and obstructive kidney
disease, in which baseline heparin-binding EGF kid-
ney expression is minimal but increases with injury [32,
34].
The abnormal whole kidney and collecting tubule cell
expression of heparin-binding EGF demonstrated in this
model of murine ARPKD could be due to one of several
causes. First, as noted above, increased heparin-binding
EGF kidney expression may be seen in a variety of in-
juries (e.g., ischemia) and may represent a more gen-
eral collecting tubule cell response to an injury. However,
this is less likely, since the expression of heparin-binding
EGF is increased in cystic cells grown in culture in which
(presumably) they are not exposed to injurious stimuli.
Alternatively, increased heparin-binding EGF may be re-
lated to the other growth factor/receptor abnormalities
(including aberrant EGFR, EGF and TGF-a expression)
demonstrated in cystic collecting tubule cells and kidneys.
Cystic epithelia have increased expression of many of
the growth factors and proto-oncogenes expressed during
kidney development [35–37]. It has been hypothesized by
several authors that the genetic defects of various PKDs
result in reversion to a more immature epithelia [37, 38].
Since heparin-binding EGF has an important role in kid-
ney development [30], it is possible that the abnormal
heparin-binding EGF expression in cystic kidneys and
cells is part of pattern of abnormal growth factor expres-
sion that may be a direct result of the underlying genetic
defect.
Immunoprecipitations of cyst fluid with antibodies di-
rected against each growth factor demonstrate the pres-
ence of all four EGF-related growth factors studied.
EGF and TGF-a immunoprecipitations show dominant
bands at approximately 6 kD, the reported size of the
secreted form. Recombinant EGF and TGF-a loaded
as positive controls migrate at the expected sizes. Am-
phiregulin immunoprecipitation shows a dominant band
at approximately 9 kD, which is consistent with reports
of soluble forms ranging in size from 9 to 50 kD [28,
29]. In contrast, heparin-binding EGF immunoprecipita-
tion also demonstrates an immunoreactive band at 9 kD,
which is smaller than the secreted forms reported in the
literature. Cyst fluid contains significant quantities of pro-
teases (W. Sweeney, unpublished observation) and, even
with the addition of protease inhibitors, it is possible that
higher molecular weight secreted forms may have under-
gone proteolytic cleavage to produce the 9 kD species.
This study also examined the relative effects of each of
the four growth factors on two physiologic processes: cell
proliferation and EGFR activation. All four EGF-related
growth factors were able to induce proliferation of both
cystic and non-cystic collecting tubule cells (Fig. 6). How-
ever, the baseline proliferation rate in cystic collecting
tubule cells was greater, and the proliferative effect of
each ligand was consistently greater in cystic compared
to control collecting tubules. This likely reflects increased
number of EGFRs (including apically expressed EGFR)
in the cystic collecting tubule cells compared to con-
trols [21]. Although each of the four growth factors had
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similar effects in stimulating cystic cells, when cyst fluid
was sequentially immunoprecipitated with antibodies
against each growth factor (Fig. 7), the greatest impact
was seen with the combined immunoprecipitation of
TGF-a and EGF (80% reduction in mitogenicity). Im-
munoprecipitation of amphiregulin had minimal effect
on residual mitogenicity, whereas heparin-binding EGF
reduced cell proliferation by an additional 10%. A signifi-
cant decrease in mitogenicity of the first control immuno-
precipitation was also seen, although the effect of TGF-a
immunoprecipitation was significantly greater than that
of the control immunoprecipitation. It is possible that the
decrease in mitogenicity seen with the first control im-
munoprecipitation was related to dilution of the sample
with the addition of antibody. Alternatively, an unidenti-
fied mitogenic stimulus could have been bound to agarose
during the initial immunoprecipitation.
Significant differences were also seen in the ability of
each EGF-related growth factor to activate EGFR. As
shown in Figure 8, in both cell lines, EGF and TGF-a
activated receptor to approximately the same degree, al-
though the effect was more pronounced in the cystic col-
lecting tubule cells. Although amphiregulin is capable of
inducing proliferation in both cell lines, amphiregulin-
induced EGFR phosphorylation in the cystic cells was
low and in the normal cells was barely detectable. This
finding suggests that low levels of receptor activation can
still result in a proliferative response. This may be a func-
tion of the duration of exposure to the growth factor. In
the proliferation assays, cells were exposed to growth fac-
tors for a full 24 hours before assessing the proliferative
response. In preliminary experiments (data not shown),
exposure for shorter durations (6 and 12 hours) did not
result in significant proliferative response. Amphiregulin
is not known to activate other members of the EGFR-
receptor “family,” so it is unlikely to be acting through a
different receptor.
In contrast, heparin-binding EGF induced a marked
increase in receptor activation compared to the other
growth factors studied. This effect was particularly
prominent in the cystic cells. There are two important
implications of this finding. First, it is possible that
heparin-binding EGF is inherently a more potent activa-
tor of EGFR. However, since increased activation does
not translate into an increased proliferative response,
this finding raises the possibility that heparin-binding
EGF activation of EGFR may have effects on cellu-
lar processes other than cell proliferation. Activation of
receptor tyrosine kinases by binding of growth factors
can induce activation of a variety of second messengers
such as cyclic adenoisine monophosphate (cAMP), PKC,
and the mitogen-activated protein (MAP) kinase signal-
ing cascade. Heparin-binding EGF has been shown to
have a role in a variety of cellular processes including cell
adherence, migration, and extracellular matrix formation
[39]. Heparin-binding EGF has also been shown to be a
mitogen for lung fibroblasts [40] and has been implicated
in the process of myofibroblast transformation in the rem-
nant kidney model [41]. Blockade of EGFR decreases re-
nal fibrosis in a rat model of ADPKD (V. Torres, personal
communication) as well as in the 5/6 nephrectomy model
of renal fibrosis [42]. In addition, angiotensin II-induced
production of the profibrotic molecule, fibronectin, is in-
hibited by both EGFR blockade and neutralizing anti-
body to heparin-binding EGF [43]. Thus, one physiologic
effect of increased receptor activation by heparin-binding
EGF could be up-regulation of profibrotic molecules.
Since the cystic kidney disease in bpk mice occurs rapidly
(death by 28 days), significant renal fibrosis does not de-
velop (unpublished observations). However, in human
ARPKD, interstitial fibrosis has a major role in the pro-
gression of renal failure. Further studies are underway to
delineate the role of EGF-related growth factors in the
development of renal fibrosis.
The second important consideration is that heparin-
binding EGF is unique among the four growth factors ex-
amined in this study in its ability to bind ErbB-4, another
member of the EGFR/ErbB “family.” When bound to lig-
and, ErbB receptors (existing as inactive heterodimers or
homodimers) undergo a conformational change that al-
lows dimerization and activation to occur [44, 45]. This, in
turn, induces receptor autophosphorylation and initiates
downstream signaling pathways. Thus, it is possible that
heparin-binding EGF could activate both EGFR/ErbB4
heterodimers and EGFR homodimers. Western analysis
for phosphorylated (activated) EGFR would not distin-
guish EGFR activated as a homodimer vs. a heterodimer.
We have previously demonstrated abnormalities in over-
all ErbB4 expression in cystic epithelium [abstract; Dell
et al, J Am Soc Nephrol 2002; 13:107A] and the relation-
ship between ErbB4 and EGFR in the cellular patho-
physiology of PKD is an area of ongoing investigation.
This study expands on previous reports of abnormal
EGF and TGF-a expression in PKD by providing new
evidence for abnormal expression of two additional EGF-
related growth factors, amphiregulin and heparin-binding
EGF, in murine ARPKD. In addition to demonstrating
abnormal expression, data from this study also highlight
potential differences in the actions of these growth fac-
tors in the pathogenesis of cystic kidney disease. These
findings and those of our previous report on TGF-a
demonstrate not only quantitative and qualitative ab-
normalities in EGF-related growth factor expression, but
also highlight the potential physiologic and pathophysio-
logic effects that growth factor overexpression may have
on cystic epithelium. In particular, the new finding of
abnormal heparin-binding EGF expression, localization
and physiologic effects could have important implications
for a variety of cellular processes and signaling pathways
involved in the disease process. In our previous work,
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we showed that treatment of cystic mice with WTACE2,
a novel inhibitor of TACE (the enzyme that mediates
shedding of both TGF-a and amphiregulin), significantly
ameliorated cystic kidney disease [7] but to a lesser extent
than treatment with an inhibitor of EGFR function [11].
One explanation is that TACE inhibition did not block the
function of all of the EGF-related growth factors that are
capable of binding EGFR. Since heparin-binding EGF
shedding may be mediated through metalloproteinases
other than TACE [12], and because membrane-bound
forms of the growth factor may have unique physiologic
roles, heparin-binding EGF may also be considered as a
potential target for therapeutic interventions in the treat-
ment of PKD.
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